Literature DB >> 16540684

Vascular proliferation is important for clinical progress of endometrial cancer.

Ingunn M Stefansson1, Helga B Salvesen, Lars A Akslen.   

Abstract

Angiogenesis is essential for tumor growth, invasion, and metastatic spread. Whereas microvessel density (MVD) has been widely used as a measure of tumor-associated angiogenesis, we now wanted to examine the significance of other angiogenic markers, especially vascular proliferation (by Ki-67/factor VIII staining) and the degree of pericyte coverage [by alpha-smooth muscle actin (alpha-SMA)/factor VIII staining], in a large and population-based series of endometrial carcinoma with complete follow-up. Due to limited information on the role of lymphangiogenesis in these tumors, lymphatic vessel density (LVD) by LYVE-1 staining was also determined, as well as selected angiogenic factors [vascular endothelial growth factor (VEGF)-A, VEGF-C, VEGF-D and basic fibroblast growth factor (bFGF)], which could possibly be related to vascular proliferation and lymphangiogenesis. The information on angiogenic phenotype was related to clinicopathologic features and disease progress. Median vascular proliferation, as estimated by vascular proliferation index (VPI), was 3.9% and high VPI was associated with features of aggressive tumors and decreased survival. The prognostic effect of VPI was superior to that of MVD. Presence of pericyte coverage, as estimated by the alpha-SMA index (SMAI), was 35% and low SMAI was significantly associated with vascular invasion by tumor cells and impaired prognosis. Peritumoral lymphatic vessels (LVD-pt) were found in 39.5% of the cases and high LVD-pt was significantly associated with aggressive tumor features and decreased survival. In multivariate survival analysis, only the extent of vascular proliferation had independent prognostic effect, in addition to well-known clinicopathologic factors, whereas MVD did not have significant prognostic value. In conclusion, our study indicates that vascular proliferation is a meaningful variable in assessing the angiogenic phenotype of endometrial carcinoma.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16540684     DOI: 10.1158/0008-5472.CAN-05-1163

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  35 in total

Review 1.  Future directions in the field of endometrial cancer research: the need to investigate the tumor microenvironment.

Authors:  A S Felix; J Weissfeld; R Edwards; F Linkov
Journal:  Eur J Gynaecol Oncol       Date:  2010       Impact factor: 0.196

2.  Gene expression patterns related to vascular invasion and aggressive features in endometrial cancer.

Authors:  Monica Mannelqvist; Ingunn M Stefansson; Geir Bredholt; Trond Hellem Bø; Anne M Oyan; Inge Jonassen; Karl-Henning Kalland; Helga B Salvesen; Lars A Akslen
Journal:  Am J Pathol       Date:  2011-02       Impact factor: 4.307

3.  MicroRNA-101 inhibits angiogenesis via COX-2 in endometrial carcinoma.

Authors:  Ying Liu; Haiyan Li; Congying Zhao; Hanbing Jia
Journal:  Mol Cell Biochem       Date:  2018-02-05       Impact factor: 3.396

Review 4.  The endometrial lymphatic vasculature: function and dysfunction.

Authors:  Jane E Girling; Peter A W Rogers
Journal:  Rev Endocr Metab Disord       Date:  2012-12       Impact factor: 6.514

5.  Pericyte depletion results in hypoxia-associated epithelial-to-mesenchymal transition and metastasis mediated by met signaling pathway.

Authors:  Vesselina G Cooke; Valerie S LeBleu; Doruk Keskin; Zainab Khan; Joyce T O'Connell; Yingqi Teng; Michael B Duncan; Liang Xie; Genta Maeda; Sylvia Vong; Hikaru Sugimoto; Rafael M Rocha; Aline Damascena; Ricardo R Brentani; Raghu Kalluri
Journal:  Cancer Cell       Date:  2012-01-17       Impact factor: 31.743

6.  Necrosis is a consistent factor to recurrence of meningiomas: should it be a stand-alone grading criterion for grade II meningioma?

Authors:  Pedro Góes; Bruno Fernandes Oliveira Santos; Fernando Seiji Suzuki; Débora Salles; João Noberto Stávale; Sérgio Cavalheiro; Manoel Antônio de Paiva Neto
Journal:  J Neurooncol       Date:  2017-12-21       Impact factor: 4.130

7.  Evaluation of Vascular Proliferation in Molecular Subtypes of Breast Cancer.

Authors:  Ionela Sevilla Bujor; Andreea Cioca; Raluca Amalia Ceaușu; Fulga Veaceslav; Cristian Nica; Anca Maria Cîmpean; Marius Raica
Journal:  In Vivo       Date:  2018 Jan-Feb       Impact factor: 2.155

8.  Insulin-like growth factor-1 induces lymphangiogenesis and facilitates lymphatic metastasis in colorectal cancer.

Authors:  Zhen-Jun Li; Xiao-Jiang Ying; Hong-Liang Chen; Ping-Jiang Ye; Zhi-Liang Chen; Gang Li; Hua-Feng Jiang; Jiang Liu; Shu-Zhen Zhou
Journal:  World J Gastroenterol       Date:  2013-11-21       Impact factor: 5.742

9.  Antitumor effects and molecular mechanisms of ponatinib on endometrial cancer cells harboring activating FGFR2 mutations.

Authors:  Do-Hee Kim; Yeonui Kwak; Nam Doo Kim; Taebo Sim
Journal:  Cancer Biol Ther       Date:  2016       Impact factor: 4.742

10.  Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance.

Authors:  George N Naumov; Monique B Nilsson; Tina Cascone; Alexandra Briggs; Oddbjorn Straume; Lars A Akslen; Eugene Lifshits; Lauren Averett Byers; Li Xu; Hua-Kang Wu; Pasi Jänne; Susumu Kobayashi; Balazs Halmos; Daniel Tenen; Xi M Tang; Jeffrey Engelman; Beow Yeap; Judah Folkman; Bruce E Johnson; John V Heymach
Journal:  Clin Cancer Res       Date:  2009-05-15       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.